Thomas Condamine

Thomas joined Carisma Therapeutics in June 2020 bringing more than 15 years of expertise in myeloid cell biology in various disease settings including oncology, as well as expertise in immune-therapy and translational sciences in early phase development. In his current role as Vice President of Discovery and translational Sciences, he is currently leading correlative studies and biomarkers analysis in support of Carisma’s clinical trial, as well as leading preclinical development.

Prior to joining Carisma Therapeutics, Thomas worked at Incyte corporation, where he was leading the translational effort in support of six large molecule targeting immune checkpoint in early clinical development and worked in close collaboration with the pre-clinical group to support several programs through IND submission. Prior to Incyte, he worked with Dr. Gabrilovich at the Moffitt Cancer Center and the Wistar Institute where he was conducting basic and translational research focused on the study of Myeloid-derived suppressor cells and Macrophage’s function in cancer.

Thomas holds an MS in Immunology from Paris XI University and a PhD in Immunology from Nantes University in France.